Non-coding RNAs as drug targets

被引:855
作者
Matsui, Masayuki [1 ,2 ]
Corey, David R. [1 ,2 ]
机构
[1] UT Southwestern, Dept Pharmacol, Dallas, TX 75390 USA
[2] UT Southwestern, Dept Biochem, Dallas, TX 75390 USA
基金
美国国家卫生研究院;
关键词
ANTISENSE OLIGONUCLEOTIDES; BCL-2; ANTISENSE; MOLECULAR-MECHANISMS; BINDING-SPECIFICITY; MYOTONIC-DYSTROPHY; CRITICAL REGULATOR; ADVANCED MELANOMA; ANGELMAN SYNDROME; MESSENGER-RNA; NUCLEAR-RNA;
D O I
10.1038/nrd.2016.117
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Most of the human genome encodes RNAs that do not code for proteins. These non-codingRNAs (ncRNAs) may affect normal gene expression and disease progression, making them a new class of targets for drug discovery. Because their mechanisms of action are often novel, developing drugs to target ncRNAs will involve equally novel challenges. However, many potential problems may already have been solved during the development of technologies to target mRNA. Here, we discuss the growing field of ncRNA including microRNA, intronic RNA, repetitive RNA and long non-coding RNA and assess the potential and challenges in their therapeutic exploitation.
引用
收藏
页码:167 / 179
页数:13
相关论文
共 145 条
[1]   Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications [J].
Aartsma-Rus, Annemieke ;
Van Ommen, Gert-Jan B. .
RNA, 2007, 13 (10) :1609-1624
[2]   Frontiers and Approaches to Chemical Synthesis of Oligodeoxyribonucleotides [J].
Abramova, Tatyana .
MOLECULES, 2013, 18 (01) :1063-1075
[3]   miR-34: from bench to bedside [J].
Agostini, Massimiliano ;
Knight, Richard A. .
ONCOTARGET, 2014, 5 (04) :872-881
[4]   Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature [J].
Anderson, EM ;
Miller, P ;
Ilsley, D ;
Marshall, W ;
Khvorova, A ;
Stein, CA ;
Benimetskaya, L .
CANCER GENE THERAPY, 2006, 13 (04) :406-414
[5]  
[Anonymous], 2007, Drugs R D, V8, P321
[6]  
[Anonymous], 2015, FDA BRIEF DOC PERIPH
[7]  
[Anonymous], 2003, NAT CELL BIOL, V5, P489, DOI DOI 10.1038/NCB0603-490
[8]   Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss [J].
Arun, Gayatri ;
Diermeier, Sarah ;
Akerman, Martin ;
Chang, Kung-Chi ;
Wilkinson, J. Erby ;
Hearn, Stephen ;
Kim, Youngsoo ;
MacLeod, A. Robert ;
Krainer, Adrian R. ;
Norton, Larry ;
Brogi, Edi ;
Egeblad, Mikala ;
Spector, David L. .
GENES & DEVELOPMENT, 2016, 30 (01) :34-51
[9]   Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group [J].
Bedikian, Agop Y. ;
Millward, Michael ;
Pehamberger, Hubert ;
Conry, Robert ;
Gore, Martin ;
Trefzer, Uwe ;
Pavlick, Anna C. ;
DeConti, Ronald ;
Hersh, Evan M. ;
Hersey, Peter ;
Kirkwood, John M. ;
Haluska, Frank G. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4738-4745
[10]   Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial' [J].
Bedikian, Agop Y. ;
Garbe, Claus ;
Conry, Robert ;
Lebbe, Celeste ;
Grob, Jean J. .
MELANOMA RESEARCH, 2014, 24 (03) :237-243